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Abstract
Background—Genome-wide association studies (GWAS) in healthy populations have identified
variants associated with erythrocyte traits, but genetic causes of hemoglobin (Hgb) variation in
children with CKD are incompletely understood.
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Methods—The Pediatric Investigation of Genetic Factors Linked with Renal Progression
(PediGFR) Consortium comprises three pediatric CKD cohorts: Chronic Kidney Disease in
Children (CKiD), Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression
of CRF in Pediatric Patients (ESCAPE) and Cardiovascular Comorbidity in Children with CKD
(4C). We performed cross-sectional and longitudinal association studies of single-nucleotide
polymorphisms (SNPs) in 1,125 patients.
Results—Children of European (n=725) or Turkish (n=400) ancestry (EA or TA) were included.
In cross-sectional analysis, 2 SNPs (rs10758658, rs12718597) previously associated with RBC
traits were significantly associated with Hgb levels in children of EA and TA. In longitudinal
analysis, SNP rs2540917 was nominally associated with Hgb in EA and TA children.
Conclusions—SNPs associated with erythrocyte traits in healthy populations were marginally
significant for an association with Hgb. Further analyses/replication studies are needed in larger
CKD cohorts to investigate SNPs of unknown significance associated with Hgb. Functional studies
will be required to confirm that the observed associations between SNPs and clinical phenotype
are causal.

Author Manuscript

Introduction

Author Manuscript

Anemia is a prevalent comorbidity in children with chronic kidney disease (CKD),
attributable to a number of physiologic factors including impaired erythropoiesis, iron
deficiency, and inflammation/iron restriction.[1] Despite the high prevalence of anemia in
this population, there is substantial variation in individual hemoglobin (Hgb) levels at any
given glomerular filtration rate (GFR), as well as by race/ethnicity and nationality.[2–4]
Well-established differences in normative hemoglobin levels in individuals of European vs.
African ancestry (both healthy and with CKD)[4,5], along with recent studies showing that
specific genetic variants are associated with a variety of red blood cell traits [6–8], suggest
that genetic variability is also a significant contributor to the risk for anemia, but currently
the genetic causes of hemoglobin variation in children with CKD are incompletely
understood.
Most children with the anemia of CKD receive standard treatment with erythropoiesis
stimulating agents (ESA) and iron supplementation, but the prevalence of treatment-resistant
anemia is high.[9] In light of adult clinic trial data regarding the adverse cardiovascular
outcomes associated with the use of escalating erythropoiesis stimulating agent (ESA) doses
and observational evidence in children that higher ESA doses are associated with increased
risk for mortality [3,10–12], it would be useful to determine how genetic variation
Pediatr Res. Author manuscript; available in PMC 2019 February 15.
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contributes to hemoglobin variability, decline, and resistance to anemia treatment in patients
with kidney disease, and if the effects are magnified in this population.

Author Manuscript

Genome-wide association studies (GWAS) allow for the identification of genomic regions in
individuals where genetic variations, or single-nucleotide polymorphisms (SNPs), are
associated with unique phenotypes.[13,14] GWAS provide a unique opportunity to delineate
the genetic epidemiology and molecular basis of a variety of CKD comorbidities including
anemia.[14] A 2009 cross-sectional GWAS in 24,167 European-ancestry individuals showed
that lower hemoglobin levels were associated with SNPs in genes known to regulate
erythropoiesis and red cell membrane function, iron homeostasis, and hepcidin expression.
[6] In addition, a GWAS in healthy children identified genetic variants cross-sectionally
associated with a variety of erythrocyte traits [7], but these associations have not been
previously studied in children with CKD, in whom the effects may be more pronounced due
to kidney disease-associated erythropoietin deficiency/dysregulation and iron restriction. In
turn, the goal of this analysis was to investigate the cross-sectional association of
hemoglobin in children with CKD with SNPs previously identified as associated with
hemoglobin levels in community-based adult and pediatric populations.[6,7] In addition, we
sought to determine whether any of these SNPs are associated with hemoglobin decline over
time in the setting of progressive CKD.

Materials and Methods
Sample Description

Author Manuscript

We utilized the genotype and phenotypic data on hemoglobin in the Pediatric Investigation
for Genetic Factors Linked to Renal Progression (PediGFR) Consortium. PediGFR is
composed of 3 studies of CKD in children; the Chronic Kidney Disease in Children (CKiD)
cohort study (n=262), the Effect of Strict Blood Pressure Control and ACE Inhibition on
Progression of Chronic Renal Failure in Pediatric Patients (ESCAPE) trial (n=273), and the
Cardiovascular Comorbidity in Children with CKD (4C) study (n=590).[15–17] Each
participating study was approved by its respective Institutional Review Board, and all study
subjects or parents/legal guardians provided informed consent for participation in the study
and genetic research. In this analysis, participants were excluded if they self-reported nonEuropean or non-Turkish ancestry.
SNP genotyping and imputation

Author Manuscript

Using a candidate marker approach, we sought to determine the association between genetic
variation and hemoglobin levels in these pediatric CKD cohorts via the analysis of the most
promising SNP markers identified previously. Hemoglobin was measured locally at
individual study sites. DNA was genotyped using the Illumina® Infinium 2.5M-8
microarray, and genotype imputation was performed according to standard protocols [18]
separately for each group using SHAPEIT v2.r644 [19] and IMPUTE2 v2.3.0 [20]. Phased
haplotypes from the 1000 Genomes project [21] were used as the reference panel. Details of
genotyping, imputation, and quality control have been previously described.[13] Twentyfour previously reported SNPs associated with red blood cell traits were included for the
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analysis.[6,7] All candidate SNPs and subjects included in the analysis passed the quality
control.
Statistical Analysis

Author Manuscript

Standard descriptive statistics such as mean, standard deviation, and frequency were used to
summarize the patient characteristics. The distribution of the outcome variable was assessed
graphically in order to meet the normality assumption for modeling. For each candidate
SNP, linear mixed-effects models were used to assess the association of hemoglobin
measured repeatedly over time and allelic dosage of the SNP obtained from imputation. This
model accounts for within-subject correlation due to repeated measures by including
subject-specific random effect. Models were adjusted for age at baseline, cohort indicator
(CKiD, ESCAPE, or 4C), and the first three components from the principle components
analysis (PCA) to account for potential population stratification. Medication use (iron, ESA,
angiotensin converting enzyme inhibitors) was included in models as the percentage of time
(months prescribed medication/ total months of follow up) on each of the medications.
Estimated glomerular filtration rate (eGFR) based on height and serum creatinine [22] as
well as its interaction with SNP dosage was included as time-varying covariates. Separate
analyses were conducted for different ethnicity groups. Cross-sectional analysis was
performed on baseline hemoglobin by linear regression models for each candidate SNP.
Similarly, cohort indicator, age and eGFR at baseline, medications use at baseline, and the
first three components from PCA, were included in the linear regression models. False
discovery rate (FDR) was applied to correct for multiple testing. SNP annotation was
performed using SNiPA [23] (http://snipa.helmholtz-muenchen.de/snipa/), the UCSC
Genome Browser [24] (https://genome.ucsc.edu/), and the data from the Sankaran lab [25]
(http://www.bloodgenes.org/RBC_MPRA/view/index.html).

Author Manuscript

Results
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We conducted a candidate SNP association study in our pediatric population of 1,125
children of European (n=725) or Turkish (n=400) ancestry. Baseline characteristics and
follow-up time for subjects by ethnicity and study cohort are presented in Table 1. Median
GFR at baseline was noted to be higher in the children in the CKiD cohort compared to the
other study cohorts. In terms of medication use at baseline, a higher proportion of children
of European ancestry enrolled in the 4C cohort were treated with an ESA at baseline
compared to the other groups. No ESCAPE subjects were treated with ACE-inhibitors at
baseline, given that it was a trial in which an ACE-inhibitor was the intervention of interest.
Children of Turkish ancestry enrolled in the 4C cohort had the highest prevalence of iron use
at baseline. Children of European ancestry enrolled in CKiD demonstrated the longest
median follow-up time at 4.89 years, with 4C subjects of both ethnicities followed for just
under 2 years.
Cross-sectional Analysis
Table 2 displays results of a cross-sectional analysis of the association of SNPs with
hemoglobin at baseline. Among children of European ancestry, two SNPs (rs10758658 and
rs12718597) were significantly associated with hemoglobin (p = .012 and .044 respectively).
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These two SNPs also showed marginal significance in children of Turkish ancestry, as did
rs2075671. In addition, in the Turkish cohort, four SNPs (rs17218597, rs2540917,
rs7255045, and rs857721) were identified to be significantly associated with hemoglobin (p
< .05). Effects on hemoglobin were all of a similar magnitude in the model adjusted for
other covariates. However, none of the SNPs passed the threshold after FDR correction for
multiple testing.
Longitudinal Analysis

Author Manuscript

Table 3 summarizes results of longitudinal analysis of the association between SNPs and
hemoglobin measured over time. In children of European ancestry, the two SNPs
(rs10758658 and rs12718597) associated (marginally) with baseline hemoglobin in both
European and Turkish cohorts were also marginally significant in longitudinal analysis (p = .
074 and .083). Among the two SNPs, rs10758658 was also observed to be significant in
Turkish children (p = .016). Three additional SNPs (rs2540917, rs7255045, and rs7385804)
were identified in longitudinal analysis (p < .0001, p = .0047, and p = .013, respectively) in
children of European ancestry, among which the SNP rs2540917 also showed significant
association in Turkish children (p = .004). There was an additional SNP (rs9483788)
identified to be marginally associated with hemoglobin in Turkish children (p = .047). Effect
size of association with hemoglobin was of a similar magnitude for all the identified SNPs
adjusted for other covariates.

Discussion

Author Manuscript
Author Manuscript

We performed cross-sectional and longitudinal analyses to examine the associations between
Hgb and 24 SNP genotypes previously identified in cross-sectional analyses to be associated
with hematological traits in both adults and children [6,7], in a cohort of children with CKD
of European and Turkish ancestry. Among the previously reported loci, 7 reached
significance for an association with Hgb at baseline (2 in both Europeans and Turks and an
additional 5 in Turks only), while 6 reached significance for an association with longitudinal
change in Hgb (2 in both Europeans and Turks, 3 in Europeans only and 1 in Turks only).
SNPs rs12718597 and rs10758658, intron variants within the IKZF1 and RCL1 genes
respectively, were associated with Hgb both cross-sectionally and longitudinally among
children of European ancestry, while the SNP on the RCL1 gene was also associated with
Hgb both at baseline and longitudinally among children of Turkish ancestry.[23,24] Both the
IKZF1 and RCL1 genes are associated with mean corpuscular volume (MCV) [23,24], a
measure of the average volume of red cells that is often positively correlated with Hgb.[26]
rs2540917, which was associated with Hgb both cross-sectionally and longitudinally in
children of Turkish ancestry, has in previously published studies been suggested to be on the
BCL11A gene[6], which has also been associated with MCV.[27] The transcription factor
BCL11A is one of the most potent known regulators of the fetal-to-adult Hgb switch/fetal
Hgb silencing that occurs shortly after birth, and is considered a promising therapeutic target
in the setting of sickle cell disease and ß-thalassemia.[28] However, in our annotation we
were unable to confirm a specific gene or erythrocyte trait associated with rs2540917.
Similarly rs172629, which we found to be cross-sectionally associated with Hgb in Turks,
has been previously reported to be on the KIT gene and associated with MCV [6]; our
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annotation did not confirm a specific gene or red cell trait association for this intergenic
variant.

Author Manuscript

Other genes on which SNPs were associated with Hgb in our analysis have been associated
with MCV (rs7255045, RTDBN), hematocrit (rs7385804, TFR2; and rs9483788,HBS1L/
MYB), or other erythrocyte phenotypes (rs2075671,ZAN; and rs857721, SPTA1).[23,24]
The KIT and RTBDN genes have roles in hematopoiesis and retinoid binding, respectively.
[6] TFR2 (transferrin receptor 2) mediates cellular uptake of transferrin-bound iron and is
involved in iron metabolism, while HBS1L/MYB is a quantitative trait locus controlling
fetal Hgb and erythrocyte volume and hemoglobin content.[6,27] Although not all of the
SNPs most strongly associated with Hgb in this analysis are intron variants which may limit
their biologic plausibility as regulators of red cell phenotype, some may be linked SNPs
which do not reside within a specific gene or affect protein function, but nevertheless may
correspond to a particular red cell response.[29] An estimated ~80% of the phenotypic
heritability in common traits may be explained by non-coding regulatory variants, which
may alter the regulation of gene transcription.[25] However, establishing the causality of
GWAS-identified regulatory variants entails identification of target genes and demonstration
of molecular function and connection to phenotype, which are beyond the scope of the
present study.[25]

Author Manuscript
Author Manuscript

Our results also highlight loci which demonstrate a differential association with hemoglobin
between different ancestral groups. Both at baseline and longitudinally, a SNP on the RCL1
gene was associated with a higher or increasing hemoglobin in Europeans compared to a
lower or decreasing hemoglobin in Turks. Similarly, rs2540917 was associated with a
longitudinal decrease in hemoglobin in Europeans while the opposite association was
observed in Turks. While the observation of opposite associations for a causal variant
between studies sampled from one population may be unexpected, opposite associations
across different ethnic groups do occur and have been reported in other studies [30,31], and
may be explained by population differences. For example, opposite associations may
indicate heterogeneous effects of the genetic variant resulting from different genetic
background. It is known that linkage disequilibrium (LD) patterns of the same genetic region
can differ between ethnic populations [32,33], leading to inconsistent association patterns
when non-causal variants are tested [34]. Therefore, if different LD structures are present in
our samples across the region and the SNP being tested is not causal, it is possible to see the
opposite associations between the two populations. In addition, this phenomenon is also
likely the result of the complex interplay of multiple loci and environmental factors which
may confound the association with hemoglobin levels. Examining the association between a
single locus and the outcome of interest fails to account for multi-locus effect or take into
account correlations with other causal variants. Differences in the minor allele frequency for
each of these SNPs by ethnicity may also explain the observed differential association with
hemoglobin. Despite adjustment for principal components, there may be additional,
ancestry-specific confounders of the association between SNPs of interest and hemoglobin
such as differences in the prevalence of thalassemias between subjects of European and
Turkish ancestry to account for differential findings.

Pediatr Res. Author manuscript; available in PMC 2019 February 15.
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Our study does have limitations. Given the relatively small sample size of our cohort, we
were limited to a candidate gene approach to identifying relevant SNPs, as the cohort would
be underpowered for a GWAS; this precluded the identification of novel SNPs associated
with Hgb in this cohort.[35]Small sample size also limits interpretation of nominal vs.
genome-wide significance of results, but the presence of an association between specific
SNPs and Hgb in both ancestry cohorts is suggestive of an association despite the lack of
significance after multiple correction. Given the low prevalence of CKD in children, there is
currently no larger group of subjects in which to explore this association. Due to limitations
of the available hematologic data in PediGFR subjects, we were restricted to Hgb as the
single marker of erythrocyte phenotype in this analysis, rather than examining a wide variety
of erythrocyte traits as in previously reported studies. However, many of the previously
examined phenotypes including MCV are positively correlated with Hgb. Anemia-targeted
therapies including ESA and iron supplements were included in the analysis as percentage of
observed time subjects were prescribed the interventions, but data on specific ESA and iron
dose were not available for all subjects; thus, we were not able to additionally account for
the effects of ESA or iron dose changes on Hgb. There was variation in subject follow up
time by study cohort, which may have limited our ability to observe a change in Hgb in
subjects followed for shorter periods of time. The previously identified SNPs we examined
were noted to be cross-sectionally associated with hemoglobin in community based cohorts
[6,7]; a risk allele for lower hemoglobin may not necessarily be associated with faster
hemoglobin decline, limiting the interpretation of our longitudinal analysis. Finally, given
the restricted ethnicities of children included in this analysis, these findings may not be
generalizable to all children with CKD and in particular to children of African ancestry.
However, to our knowledge this is the first study to explore the genetic contribution to red
cell phenotype in children with CKD.
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Our results confirming the association between a subset of previously identified SNPs and
hemoglobin provide additional evidence supporting these associations in children. Among
some of the variants associated with differences in red blood cell traits, it is possible that the
effects on hemoglobin are more pronounced among children with the conditions of
erythropoietin dysregulation, iron restriction, and inflammation that commonly emerge in
advancing CKD. Thus it is crucial step toward the application of precision medicine to test
these results among children with CKD, in whom the biologic implications and potential
treatment options are most relevant.

Author Manuscript

In conclusion, we demonstrate for the first time that SNPs previously reported to be
associated with erythrocyte traits were nominally significant for an association with Hgb in
children of European and Turkish ancestry with CKD. Differences in single SNPs are
unlikely to account for most of the variability in Hgb levels observed in children with CKD.
However, in the case of larger observed effect sizes, there is potential for these findings to
yield prognostic information that may, in the future, guide individualized pharmacologic
decisions in the treatment of the anemia of CKD. Moving forward, we will plan for further
analyses/replication studies in larger adult CKD cohorts (such as the Chronic Renal
Insufficiency Cohort Study [CRIC]) to investigate SNPs of unknown significance that appear
to be associated with Hgb. Functional studies will be required to confirm that the observed
associations between SNPs of interest and clinical phenotype are causal.
Pediatr Res. Author manuscript; available in PMC 2019 February 15.
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30 (11.5%)
118 (45%)
72 (27.5%)
230 (87.8%)

5.1 ± 1.9
4.19 ± 2.02

Iron treated – n(%)

Non-Glomerular CKD – n (%)

Number of Visits, mean (SD)

Follow-Up Period, yrs – mean (SD)

43.2 (33.1–54.7)

ACEi treated – n (%)

- median (IQR)

95 (36.3%)

11.1 (7.4–14.4)

ESA treated – n (%)

eGFR,

ml/min/1.73m2

Female, n (%)

Age, yrs - median (IQR)

CKiD
(n=262)

185 (87.3%)

23 (10.8%)

0 (0%)

16 (7.5%)

36.1 (25.1–45.1)

88 (41.5%)

11.8 (8.6–15.1)

4.46 ± 2.21

22.6 ± 12.0

4C
(n=339)

1.70 ± 1.04

4.2 ± 2.0

315 (92.9%)

158 (46.6%)

113 (33.3%)

55 (16.2%)

25.9 (17.6–34.3)

127 (37.5%)

2.82 ± 2.06

15.7 ± 10.3

53 (86.9%)

24 (39.3%)

0 (0%)

8 (13.2%)

27.5 (19.5–46.3)

28 (45.9%)

12.0 (10.1–14.3)

Escape
(n=61)

Turkish Ancestry

12.4 (9.5–15.3)

Longitudinal Characteristics

1.78 ± 1.06

4.0 ± 2.0

198 (78.9%)

81 (32.3%)

119 (47.4%)

89 (35.5%)

25.1 (17.1–34.4)

76 (30.3%)

Escape
(n=212)
Baseline Characteristics

12.1 (8.9–15.0)

4C
(n=251)

European Ancestry

Demographic and Clinical Characteristics at Baseline and Follow-Up Time in 1,125 Children

Author Manuscript
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0.051

0.056

0.038

0.051

0.031

0.036

0.030

rs10758658

rs12718597

rs172629

rs2075671

rs2540917

rs7255045

rs857721

0.19

0.19

0.19

0.19

0.19

0.19

0.19

0.052

0.29

Adjusted
p-value

Minor Allele
Frequency

.37

.19

.62±.28

.71±.34

.56±.26

.69±.35

.74±.35

.49±.25

−.68±.35

.27

.23

.29

.16

.20

.39

.15

Turkish Ancestry

.36±.18

.53±.21

European Ancestry

Coefficient
Estimate ± SD

1

19

2

7

4

7

9

7

9

Chromosome

A, MCHC

A, MCV

C, MCV

A, RBC

G, MCV

A, MCV

A, MCH

A, MCV

A, MCH

Reference
allele and
assoc. trait in
CHARGE6

−.0022

−.0037

−.0031

.0086

−.0043

.0032

−.0048

.0032

−.0048

Model adjusted for age at baseline, eGFR, ESA use, iron use, ACEi use, cohort indicator, and the first 3 PCA componentMCH – mean corpuscular hemoglobin; MCV – mean corpuscular volume; MCHC
– mean corpuscular hemoglobin concentration; RBC – red blood cell count

*

0.044

0.012

rs12718597

rs10758658

SNP

Unadjusted
p-value

Coefficient
Estimate in
CHARGE6

Author Manuscript

Significant Results of Multivariate* Cross-Sectional Analysis of SNP and Hemoglobin

Author Manuscript

Table 2.
Atkinson et al.
Page 11

Pediatr Res. Author manuscript; available in PMC 2019 February 15.

Author Manuscript

Author Manuscript

0.083

<0.001

0.0047

0.013

0.016

0.004

0.047

rs12718597

rs2540917

rs7255045

rs7385804

rs10758658

rs2540917

rs9483788

0.37

0.096

0.19

0.10

0.06

<0.002

0.40

0.40

Adjusted
p-value

Minor Allele
Frequency

.39

.31

.44

.37

.19

−.37±.17

.45±.005

−.52±.007

.22

.29

.15

Turkish Ancestry

.30±.12

−.37±.13

−.57±.12

.20±.11

.27±.15

European Ancestry

Coefficient
Estimate ± SD

6

2

9

7

19

2

7

9

Chromosome

C, Hct

C, MCV

A, MCH

C, Hct

A, MCV

C, MCV

A, MCV

A, MCH

Reference allele
and assoc. trait
in CHARGE6

.2172

−.0031

−.0048

−.1592

−.0037

−.0031

.0032

−.0048

Model adjusted for age at baseline, eGFR, ESA use, iron use, ACEi use, cohort indicator, and the first 3 PCA components MCH – mean corpuscular hemoglobin; MCV – mean corpuscular volume;
MCHC – mean corpuscular hemoglobin concentration

*

0.074

Unadjusted
p-value

rs107586588

SNP

Coefficient
Estimate
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Significant Results of Multivariate* Longitudinal Analysis of SNP and Hemoglobin
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